메뉴 건너뛰기




Volumn 31, Issue 8, 2011, Pages 2651-2656

Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer

Author keywords

Angiogenic factors; Angiogenin; Cervical cancer; Endoglin; Endostatin

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ENDOGLIN; ENDOSTATIN;

EID: 79961183392     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (27)

References (42)
  • 5
    • 70749125099 scopus 로고    scopus 로고
    • Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study
    • Moore DH, Tian C, Monk BJ, Long HJ, Omura GA and Bloss JD: Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 116: 44-49, 2010.
    • (2010) Gynecol Oncol , vol.116 , pp. 44-49
    • Moore, D.H.1    Tian, C.2    Monk, B.J.3    Long, H.J.4    Omura, G.A.5    Bloss, J.D.6
  • 6
    • 69249104203 scopus 로고    scopus 로고
    • Cervical cancer therapy: Current, future and anti-angiogensis targeted treatment
    • Willmott LJ and Monk BJ: Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Rev Anticancer Ther 9: 895-903, 2009.
    • (2009) Expert Rev Anticancer Ther , vol.9 , pp. 895-903
    • Willmott, L.J.1    Monk, B.J.2
  • 7
    • 73949119408 scopus 로고    scopus 로고
    • Anti-angiogenesis agents in metastatic or recurrent cervical cancer
    • Monk BJ, Willmott LJ and Sumner DA: Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 116: 181-186, 2010.
    • (2010) Gynecol Oncol , vol.116 , pp. 181-186
    • Monk, B.J.1    Willmott, L.J.2    Sumner, D.A.3
  • 8
    • 69249184415 scopus 로고    scopus 로고
    • Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas
    • Fujimoto J: Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 29: 2665-2669, 2009.
    • (2009) Anticancer Res , vol.29 , pp. 2665-2669
    • Fujimoto, J.1
  • 10
    • 38949132628 scopus 로고    scopus 로고
    • Chemotherapy for advanced, recurrent, and metastatic cervical cancer
    • Moore DH: Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 6: 53-57, 2008.
    • (2008) J Natl Compr Canc Netw , vol.6 , pp. 53-57
    • Moore, D.H.1
  • 12
    • 33750173608 scopus 로고    scopus 로고
    • Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer
    • DOI 10.1016/j.ygyno.2006.03.023, PII S009082580600254X
    • Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW and Rader JS: Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103: 489-493, 2006. (Pubitemid 44602157)
    • (2006) Gynecologic Oncology , vol.103 , Issue.2 , pp. 489-493
    • Wright, J.D.1    Viviano, D.2    Powell, M.A.3    Gibb, R.K.4    Mutch, D.G.5    Grigsby, P.W.6    Rader, J.S.7
  • 13
    • 61549141361 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
    • Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 27: 1069-1074, 2009.
    • (2009) J Clin Oncol , vol.27 , pp. 1069-1074
    • Monk, B.J.1    Sill, M.W.2    Burger, R.A.3    Gray, H.J.4    Buekers, T.E.5    Roman, L.D.6
  • 15
    • 13844294265 scopus 로고    scopus 로고
    • Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
    • Tan BR and McLeod HL: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 32: 113-119, 2005.
    • (2005) Semin Oncol , vol.32 , pp. 113-119
    • Tan, B.R.1    McLeod, H.L.2
  • 16
    • 69349097400 scopus 로고    scopus 로고
    • Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
    • Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025, 2009.
    • (2009) Clin Cancer Res , vol.15 , pp. 5020-5025
    • Ebos, J.M.1    Lee, C.R.2    Kerbel, R.S.3
  • 17
    • 62949129110 scopus 로고    scopus 로고
    • Intricacies of bevacizumab-induced toxicities and their management
    • Gressett SM and Shah SR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43: 490-501, 2009.
    • (2009) Ann Pharmacother , vol.43 , pp. 490-501
    • Gressett, S.M.1    Shah, S.R.2
  • 18
    • 77951937790 scopus 로고    scopus 로고
    • Bevacizumab toxicities and their management in ovarian cancer
    • Randall LM and Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117: 497-504, 2010.
    • (2010) Gynecol Oncol , vol.117 , pp. 497-504
    • Randall, L.M.1    Monk, B.J.2
  • 19
    • 77951582589 scopus 로고    scopus 로고
    • Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: A review of health economic evaluations
    • Norum J, Nieder C and Kondo M: Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother 22: 75-82, 2010.
    • (2010) J Chemother , vol.22 , pp. 75-82
    • Norum, J.1    Nieder, C.2    Kondo, M.3
  • 20
    • 0036581310 scopus 로고    scopus 로고
    • Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies
    • Review
    • Schoppmann SF, Horvat R and Birner P: Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep 9: 455-460, 2002.
    • (2002) Oncol Rep , vol.9 , pp. 455-460
    • Schoppmann, S.F.1    Horvat, R.2    Birner, P.3
  • 21
    • 36049037879 scopus 로고    scopus 로고
    • Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection
    • DOI 10.1111/j.1447-0756.2007.00666.x
    • Phoophitphong T, Hanprasertpong J, Dechsukhum C and Geater A: Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J Obstet Gynaecol Res 33: 840-848, 2007. (Pubitemid 350086518)
    • (2007) Journal of Obstetrics and Gynaecology Research , vol.33 , Issue.6 , pp. 840-848
    • Phoophitphong, T.1    Hanprasertpong, J.2    Dechsukhum, C.3    Geater, A.4
  • 24
    • 0032937361 scopus 로고    scopus 로고
    • Angiogenesis in malignancies of the female genital tract
    • Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
    • (1999) Gynecol Oncol 72 , pp. 220-231
    • Abulafia, O.1    Triest, W.E.2    Sherer, D.M.3
  • 25
    • 77950690217 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
    • Carpini JD, Karam AK and Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13: 43-58, 2010.
    • (2010) Angiogenesis , vol.13 , pp. 43-58
    • Carpini, J.D.1    Karam, A.K.2    Montgomery, L.3
  • 26
    • 18844479070 scopus 로고    scopus 로고
    • Uterine cervical carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival
    • Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P and van Kaick G: Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of timeintensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58: 3598-3602, 1998. (Pubitemid 28376557)
    • (1998) Cancer Research , vol.58 , Issue.16 , pp. 3598-3602
    • Hawighorst, H.1    Knapstein, P.G.2    Knopp, M.V.3    Weikel, W.4    Brix, G.5    Zuna, I.6    Schonberg, S.O.7    Essig, M.8    Vaupel, P.9    Van Kaick, G.10
  • 29
    • 33750621551 scopus 로고    scopus 로고
    • Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers
    • DOI 10.1111/j.1440-1827.2006.02037.x
    • Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T and Tokunaga O: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56: 717-723, 2006. (Pubitemid 44691157)
    • (2006) Pathology International , vol.56 , Issue.12 , pp. 717-723
    • Minhajat, R.1    Mori, D.2    Yamasaki, F.3    Sugita, Y.4    Satoh, T.5    Tokunaga, O.6
  • 32
    • 33745068191 scopus 로고    scopus 로고
    • Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma
    • Yang LY, Lu WQ, Huang GW and Wang W: Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6: 110, 2006.
    • (2006) BMC Cancer , vol.6 , pp. 110
    • Yang, L.Y.1    Lu, W.Q.2    Huang, G.W.3    Wang, W.4
  • 33
    • 54849409198 scopus 로고    scopus 로고
    • Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
    • Ødegaard E, Davidson B, Engh V, Onsrud M and Staff AC: Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 199: 533 e531-538, 2008.
    • (2008) Am J Obstet Gynecol , vol.199
    • Ødegaard, E.1    Davidson, B.2    Engh, V.3    Onsrud, M.4    Staff, A.C.5
  • 35
    • 0031895639 scopus 로고    scopus 로고
    • Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer
    • Chopra V, Dinh TV and Hannigan EV: Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16: 152-159, 1998. (Pubitemid 28158437)
    • (1998) Cancer Investigation , vol.16 , Issue.3 , pp. 152-159
    • Chopra, V.1    Dinh, T.V.2    Hannigan, E.V.3
  • 37
    • 33344472286 scopus 로고    scopus 로고
    • Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action
    • Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.
    • (2006) Exp Cell Res , vol.312 , pp. 594-607
    • Folkman, J.1
  • 38
    • 33644543821 scopus 로고    scopus 로고
    • Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas
    • Gruszka A, Kunert-Radek J, Pawlikowski M and Stepien H: Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary 8: 163-168, 2005.
    • (2005) Pituitary , vol.8 , pp. 163-168
    • Gruszka, A.1    Kunert-Radek, J.2    Pawlikowski, M.3    Stepien, H.4
  • 39
    • 33748656557 scopus 로고    scopus 로고
    • Serum endostatin levels in gastric cancer patients: Correlation with clinicopathological parameters
    • Koç M, Göçmen E, Kiliç M, Ozbay M, Oktem M and Tez M: Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology 53: 616-618, 2006.
    • (2006) Hepatogastroenterology , vol.53 , pp. 616-618
    • Koç, M.1    Göçmen, E.2    Kiliç, M.3    Ozbay, M.4    Oktem, M.5    Tez, M.6
  • 42
    • 33344459620 scopus 로고    scopus 로고
    • Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
    • DOI 10.1038/sj.bjc.6602952
    • Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J and Boneberg EM: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531, 2006. (Pubitemid 43289756)
    • (2006) British Journal of Cancer , vol.94 , Issue.4 , pp. 524-531
    • Furstenberger, G.1    Von Moos, R.2    Lucas, R.3    Thurlimann, B.4    Senn, H.-J.5    Hamacher, J.6    Boneberg, E.-M.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.